公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2015 | AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort. | Ramalingam, Suresh S.; Yang, James Chih-Hsin; Lee, Chee Khoon; Kurata, Takayasu; Kim, Dong-Wan; John, Thomas; Nogami, Naoyuki; Ohe, Yuichiro; Rukazenkov, Yuri; Frewer, Paul; Cantarini, Mireille; Ghiorghiu, Serban; Janne, Pasi A. | J. Clin. Oncol. | | | |
2023 | Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON | Hartmaier, Ryan J; Markovets, Aleksandra A; Ahn, Myung Ju; Sequist, Lecia V; Han, Ji-Youn; Cho, Byoung Chul; Yu, Helena A; Kim, Sang-We; CHIH-HSIN YANG ; Lee, Jong-Seok; Su, Wu-Chou; Kowalski, Dariusz M; Orlov, Sergey; Ren, Song; Frewer, Paul; Ou, Xiaoling; Cross, Darren A E; Kurian, Nisha; Cantarini, Mireille; Jänne, Pasi A | Cancer discovery | 36 | 29 | |
2015 | Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer. | Oxnard, Geoffrey R.; Ramalingam, Suresh S.; Ahn, Myung-Ju; Kim, Sang-We; Yu, Helena Alexandra; Saka, Hideo; Horn, Leora; Goto, Koichi; Ohe, Yuichiro; Cantarini, Mireille; Frewer, Paul; Lahn, Michael; Yang, James Chih-Hsin | J. Clin. Oncol. | | | |